fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

UCB’s phase IIa study results of Bepranemab in early Alzheimer’s Disease selected for late-breaking symposium at 2024 CTAD Meeting

Written by | 22 Oct 2024

UCB announced that the results of its double-blind TOGETHER (AH0003) Phase IIa study of bepranemab – an investigational anti-tau antibody – in people living with prodromal to mild… read more.

FDA approval for 320 mg single-injection device presentations of Bimzelx – UCB

Written by | 17 Oct 2024

UCB  announced that the FDA has approved a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of Bimzelx (bimekizumab-bkzx). These new device presentations add to… read more.

European Commission approval for 320 mg device presentations of Bimzelx (bimekizumab) – UCB

Written by | 8 Aug 2024

UCB, a global biopharmaceutical company, announced that the European Commission (EC) has granted marketing authorization for two 320 mg device presentations of Bimzelx (bimekizumab). The pre-filled syringe and… read more.

Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps – UCB

Written by | 17 Jun 2024

New recommendations released in Epileptic Disorders by a global expert group comprising epileptologists, neurologists and pharmacologists from Europe and North America address the critical unmet needs associated with… read more.

Publication in The Lancet is announced of phase III bimekizumab trials in moderate to severe hidradenitis suppurativa – UCB

Written by | 25 May 2024

UCB, announced that The Lancet has published results from the Phase III BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of bimekizumab, an… read more.

Latest real-world evidence presented at WCO-IOF-ESCEO assesses how Evenity (romosozumab) can help to close the treatment gap in osteoporosis – UCB

Written by | 16 Apr 2024

UCB, announced key findings from the first retrospective patient cohort study in Denmark to observe the characteristics of patients selected for romosozumab treatment in routine clinical practice. The… read more.

European Commission approval of Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis – UCB

Written by | 7 Dec 2023

UCB announced that the European Commission (EC) has granted a marketing authorization for Zilbrysq (zilucoplan) as an add-on to standard therapy for the treatment of generalized myasthenia gravis… read more.

MHRA (UK) approves Bimzelx for patients with active psoriatic arthritis and adult patients with active axial spondyloarthritis – UCB

Written by | 10 Sep 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for bimekizumab (Bimzelx, UCB) for patients with active psoriatic arthritis and adult patients with active axial… read more.

FDA action for BLA for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis is now shifted to Q3 2023 – UCB

Written by | 10 Jul 2023

UCB, a global biopharmaceutical company,announced that the Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis remains under review with… read more.

FDA approval of Rystiggo for the treatment of adults with generalized myasthenia gravis – UCB

Written by | 5 Jul 2023

UCB announced Rystiggo (rozanolixizumab-noli) has been approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.